Data as of Nov 28
| -0.04 / -2.17%|
The 2 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 6.50, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a +261.11% increase from the last price of 1.80.
The current consensus among 4 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.